Ketan Patel, MD
Internal Medicine · Carrollton, TXNPI 1003814146
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,980 of the $8,944 with a category attached, or 66.9%. Biodelivery Sciences International, Inc. accounts for 73.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $7,713 and has fallen 97.8% since, to $170 in 2024. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $203.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$7K
- Pulmonx Corporation$810
- Kerecis Limited$330
- Smith+Nephew$272
- Organogenesis Inc.$235
- Stryker$154
- plus $552 from 9 others
Across 25 payments — averaging $85.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Speaking & faculty fees$5,98067%
- Travel & lodging$1,01111%
- Food & beverage$1,95322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biodelivery Sciences International, Inc. | 24 | $6,590 |
| Pulmonx Corporation | 1 | $810 |
| Kerecis Limited | 2 | $330 |
| Smith+Nephew | 2 | $272 |
| Organogenesis Inc. | 2 | $235 |
| Stryker | 1 | $154 |
| Integra Lifesciences Corporation | 1 | $128 |
| KCI USA, Inc. | 1 | $111 |
| Nevro Corp. | 1 | $109 |
| Abbott | 1 | $57 |
| Amarin Pharma, Inc. | 2 | $48 |
| Novartis | 2 | $40 |
| Novo Nordisk | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Inogen, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$6,231
- Pulmonx Endobronchial Valve EBV$810
- Kerecis Omega3 SurgiClose$612
- Kerecis Omega3 GraftGuide$330
- GRAFIX PL$272
- Kerecis Omega3 Wound$189
- Kerecis Omega3 Surgibind$189
- PuraPly$167
- SALVATION$154
- Kerecis Omega3 Marigen$141
- BILAYER WOUND MATRIX (BWM)$128
- INTEGRA WOUND MATRIX (IWM)$128
- PRIMATRIX$128
- IDRT$128
- FLOWABLE$128
- SNAP$111
- ACTIVAC$111
- VAC VERAFLO CLEANSE CHOICE$111
- PREVENA$111
- VAC VERAFLO$111
How this compares
$8,944 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 505 | $165,333 |
| IngrezzaValbenazine Tosylate | 17 | $61,699 |
| JardianceEmpagliflozin | 123 | $32,100 |
| JanuviaSitagliptin Phosphate | 100 | $26,260 |
| XareltoRivaroxaban | 77 | $20,283 |
| Atorvastatin Calcium | 1,164 | $15,125 |
| TradjentaLinagliptin | 71 | $14,514 |
| NeuproRotigotine | 16 | $14,166 |
| Gabapentin | 888 | $13,347 |
| Memantine Hcl | 397 | $12,939 |
| Potassium Chloride | 474 | $11,817 |
| EntrestoSacubitril/Valsartan | 33 | $11,249 |
| ZenpepLipase/Protease/Amylase | 37 | $9,076 |
| RexultiBrexpiprazole | 15 | $8,691 |
| Divalproex Sodium | 390 | $8,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $40 | $11,24933 claims |
| Smith+NephewSantyl | $272 | $5,43514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Carrollton
- Henry PunziCarrollton$120K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.